Spero Therapeutics, Inc. Earnings Per Share (Basic)
Spero Therapeutics, Inc. (SPRO) reported Earnings Per Share (Basic) of -$0.16 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-12
- Spero Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.16.
- Spero Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.13.
- Spero Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.13.
- Spero Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-06-30 was -$0.03.
- Spero Therapeutics, Inc. earnings per share, basic for fiscal 2025 was $0.15.
- Spero Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.27, a 395.35% decline from fiscal 2023.
- Spero Therapeutics, Inc. earnings per share, basic for fiscal 2023 was $0.43.
- Spero Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$1.23.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.16 10-Q · filed 2026-08-12 | -$0.29 10-Q · filed 2026-08-12 | ||
| 2026-03-31 | -$0.13 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $0.15 10-K · filed 2026-03-26 | |||
| 2025-09-30 | -$0.13 10-Q · filed 2025-11-13 | -$0.41 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | -$0.03 10-Q · filed 2026-08-12 | -$0.28 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | -$0.25 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | -$1.27 10-K · filed 2026-03-26 | |||
| 2024-09-30 | -$0.32 10-Q · filed 2025-11-13 | -$0.65 derived: net income ÷ weighted average shares · filed 2025-11-13 | -$0.89 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$0.33 10-Q · filed 2025-08-12 | -$0.57 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$0.24 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.43 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$0.06 10-Q · filed 2024-11-14 | -$0.29 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$0.54 10-Q · filed 2024-11-14 | $1.77 derived: net income ÷ weighted average shares · filed 2024-11-14 |
| 2023-06-30 | -$0.23 10-Q · filed 2024-08-05 | -$0.48 10-Q · filed 2024-08-05 | $1.84 derived: net income ÷ weighted average shares · filed 2024-08-05 | $1.74 derived: net income ÷ weighted average shares · filed 2024-08-05 |
| 2023-03-31 | -$0.25 10-Q · filed 2024-05-15 | $2.10 derived: net income ÷ weighted average shares · filed 2024-05-15 | $2.07 derived: net income ÷ weighted average shares · filed 2024-05-15 | $1.55 derived: net income ÷ weighted average shares · filed 2024-05-15 |
| 2022-12-31 | $2.45 derived: net income ÷ weighted average shares · filed 2024-03-13 | $2.55 derived: net income ÷ weighted average shares · filed 2024-03-13 | $2.02 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$1.23 10-K · filed 2024-03-13 |
| 2022-09-30 | -$0.33 10-Q · filed 2023-11-13 | -$1.17 derived: net income ÷ weighted average shares · filed 2023-11-13 | -$2.16 10-Q · filed 2023-11-13 | -$3.06 derived: net income ÷ weighted average shares · filed 2023-11-13 |
| 2022-06-30 | -$0.87 10-Q · filed 2023-08-10 | -$1.88 10-Q · filed 2023-08-10 | -$2.78 derived: net income ÷ weighted average shares · filed 2023-08-10 | -$3.48 derived: net income ÷ weighted average shares · filed 2023-08-10 |
| 2022-03-31 | -$1.01 10-Q · filed 2023-05-11 | -$1.91 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$2.61 derived: net income ÷ weighted average shares · filed 2023-05-11 | -$3.26 derived: net income ÷ weighted average shares · filed 2023-05-11 |
| 2021-12-31 | -$0.90 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$1.61 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$2.24 derived: net income ÷ weighted average shares · filed 2023-03-30 | -$2.91 10-K · filed 2023-03-30 |
| 2021-09-30 | -$0.70 10-Q · filed 2022-11-14 | -$1.33 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$1.99 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$0.63 10-Q · filed 2022-08-10 | -$1.29 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |